{
    "nctId": "NCT00110084",
    "briefTitle": "ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Weekly Nab (Nanoparticle Albumin Bound)-Paclitaxel (Nab-paclitaxel) (Abraxane\u00ae) in Combination With Gemcitabine in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Proportion of Patients With Confirmed Responses",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed invasive breast cancer\n\n  - Clinical evidence of metastatic disease\n\n  + No bone metastases or other non-measurable disease as the only evidence of metastasis\n* Measurable disease, defined as at least 1 measurable lesion\n\n  - The following are considered non-measurable disease:\n  * Small lesions (\\< 2 cm)\n  * Bone lesions\n  * Leptomeningeal disease\n  * Ascites\n  * Pleural or pericardial effusions\n  * Inflammatory breast disease\n  * Lymphangitis cutis or pulmonis\n  * Abdominal masses that are not confirmed and followed by imaging techniques\n  * Cystic lesions\n* HER2(human epidermal growth factor receptor 2)-positive disease allowed provided patient has received prior treatment with trastuzumab\n* No evidence of active brain metastasis, including leptomeningeal involvement\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over Sex\n* Female Menopausal status\n* Not specified Performance status\n* ECOG 0-1 Life expectancy\n* At least 12 weeks Hematopoietic\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 9 g/dL Hepatic\n* AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN Renal\n* Creatinine \u2264 1.5 mg/dL Other\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 30 days after completion of study treatment\n* No pre-existing peripheral neuropathy \\> grade 1\n* No other clinically significant illness or significant medical condition that would preclude study participation\n* No history of allergy or hypersensitivity to paclitaxel protein-bound particles in an injectable suspension, paclitaxel, gemcitabine, albumin, drug product excipients, or agents that are chemically similar to study drugs\n* No serious medical risk factors involving any of the major organ systems that would preclude study participation\n* No active stage III or IV invasive non-breast malignancy within the past 5 years\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* See Disease Characteristics Chemotherapy\n* No more than 1 prior adjuvant chemotherapy regimen\n* No prior chemotherapy for metastatic disease\n* At least 6 months since prior adjuvant or neoadjuvant taxane\n* More than 2 weeks since prior cytotoxic chemotherapy\n* Prior neoadjuvant chemotherapy allowed\n* No other concurrent chemotherapy Endocrine therapy\n* Prior hormonal treatment as adjuvant therapy or for metastatic disease allowed Radiotherapy\n* Prior radiotherapy to target lesion allowed provided there is evidence of disease progression after completion of treatment\n* More than 2 weeks since prior radiotherapy, except radiotherapy to a non-target lesion only or single-dose palliative radiotherapy\n* No concurrent radiotherapy Surgery\n* Not specified Other\n* More than 2 weeks since prior investigational drugs\n* No concurrent participation in another clinical trial that is studying investigational procedures or therapies\n* Concurrent bisphosphonates (e.g., pamidronate or zoledronate) allowed for palliation of pain or lytic lesions from breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}